We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Single Gene Mutation Linked to Severe Atopic Dermatitis

By LabMedica International staff writers
Posted on 05 Jul 2017
Print article
A mutation in the CARD11 gene has been linked to the development of the severe allergic skin disease atopic dermatitis (eczema).

The link between the CARD11 mutation and atopic dermatitis was discovered through gene analysis of eight individuals suffering from severe atopic dermatitis from four families. Each of the four families had a distinct mutation that affected a different region of the CARD11 (Caspase recruitment domain-containing protein 11) protein, but all the mutations had similar effects on T-cell signaling.

The CARD11 gene encodes a scaffolding protein involved in lymphocyte receptor signaling. CARDs (Caspase activation and recruitment domains) are interaction motifs found in a wide array of proteins, typically those involved in processes relating to inflammation and apoptosis. These domains mediate the formation of larger protein complexes via direct interactions between individual CARDs. CARD domains are found on a strikingly wide range of proteins, including helicases, kinases, mitochondrial proteins, caspases, and other cytoplasmic factors.

Transfection of the mutant CARD11gene into T-cell lines grown in laboratory culture demonstrated both loss-of-function and dominant-interfering activity upon antigen receptor–induced activation of nuclear factor-kappaB and mammalian target of rapamycin complex 1 (mTORC1). Patient T-cells had similar defects, as well as low production of the cytokine interferon-gamma (IFN-gamma). The mTORC1 and IFN-gamma production defects were partially rescued by supplementation with the amino acid glutamine, which requires CARD11 for import into T-cells.

This study was carried out by the [U.S.] National Institute of Allergy and Infectious Diseases (Bethesda, MD, USA) and was published in the June 19, 2017, online edition of the journal Nature Genetics.

Related Links:
National Institute of Allergy and Infectious Diseases

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Calprotectin Assay
Fecal Calprotectin ELISA
New
Ultrasonic Cleaner
UC 300 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.